Skip to main content
Premium Trial:

Request an Annual Quote

Upstate to Sell Galapagos Adenovirus Products; Could Play in siRNA Market

NEW YORK, May 17 (GenomeWeb News) - Upstate, a wholly owned subsidiary of Serologicals, will market and sell Galapagos' adenovirus products worldwide, excluding Japan, Galapagos said today.

 

In return, Galapagos will receive double-digit royalties on net sales achieved by Upstate.

 

A "hallmark" of the adenovirus technology is the stability of the knock-in and knock-down protein levels, and the suitability for high-throughput assays using human primary cells, Upstate said.

 

These features should allow the adenovirus technology to compete effectively in the global market for siRNA reagents. Galapagos retains rights to continue servicing its existing customers for these products.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.